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Abstract
Calcification is one of the most common issues that arise concerning biocompatibility, 
known to affect many systems in the body. It is often associated with an increase in free 
phosphate and calcium particles in the serum that leads to mineral deposition. Calcification 
is problematic both in the naturally occurring state of the body, as well as when it exists 
as result of biomaterial implants. While calcification is prominent in many different forms, 
not all mechanisms and processes associated with the phenomenon are completely under-
stood. In this chapter, materials affected by calcification, potential mechanisms of action, 
and potential treatments will be discussed. Both bioprosthetic and polymer heart valves 
and urinary implants will be evaluated for material composition, application, and failure. 
Current research on the assessment of these materials will be reported, with the associ-
ated chemical and biological mechanisms explained. The chapter will also detail diseased 
states of the arteries that induce calcification and what treatments can be used for both arte-
rial and bioprosthetic calcification. Finally, the chapter will conclude by detailing future 
designs for biomaterials to prevent and treat calcification in both natural and synthetic 
applications.
Keywords: aortic valves, biomaterials, bioprosthetic, calcification, tissue engineering, 
urinary regeneration
1. Introduction
Calcification is one of the most common issues that arise concerning biocompatibility, known 
to affect many systems in the body. It is often associated with an increase in free phosphate 
and calcium particles in the serum that leads to mineral deposition [1]. Calcification is prob-
lematic both in the naturally occurring state of the body, as well as when it exists as result 
of biomaterial implants [2]. While recent research confirms that it is an active, cell-mediated 
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process rather than a passive association of age, the various mechanisms of calcification and 
related factors that are involved with this phenomenon are still not completely understood.
The cardiovascular system is one that is majorly affected by calcification, both naturally and 
via biosynthetic and bioprosthetic implants. Natural vascular calcification is associated with 
the stiffening of arterial walls and the deposition of free calcium and phosphate particles in 
the serum [3]. Vascular calcification is also seen to increase in patients on dialysis, due to 
serum being stripped of natural inhibitors of mineralization [4]. Valve implants, coronary 
stents, and balloon angioplasty are all affected by mineralization due to immune response of 
biomaterials used, calcium affinity, or even elastin/collagen injury post-implantation [5]. The 
consequence of this calcification is often associated with implant failure and stiffness of tissue. 
This also occurs in implants in the urinary system due to adhesion of various minerals and 
cells to the surface of the implant [6]. Implants such as urinary catheters and ureteral stents 
calcify as a result of interaction of the bacteria and the device.
While calcification is prominent in many different forms, not all mechanisms and processes 
associated with the phenomenon are completely understood. In this chapter, materials 
affected by calcification, potential mechanisms of action, and potential treatments will be 
discussed. Both bioprosthetic and polymer heart valves and urinary implants will be evalu-
ated for material composition, application, and failure. Current research on the assessment 
of these materials will be reported, with the associated chemical and biological mechanisms 
explained. The chapter will also detail diseased states of the arteries that induce calcification 
and what treatments can be used for both arterial and bioprosthetic calcification. Finally, the 
chapter will conclude by detailing future designs for biomaterials to prevent and treat calcifi-
cation in both natural and synthetic applications.
2. Heart valves
A major contributor to morbidity and mortality worldwide is valvular heart diseases (VHDs). 
Valvular dysfunction is related to an insufficient opening or closing of the valve caused by 
either stenosis, regurgitation or both [7]. Stenosis can be described as a stiffening of the leaflets, 
leading to improper opening and closing of the valves. Regurgitation occurs when blood flows 
back through the valve indicating inadequate valve closure [8]. Almost 2.5% of the U.S. popu-
lation is affected by VHDs. With 300,000 surgeries completed annually, heart valve replace-
ments come in second for the most common cardiovascular surgical procedure to treat this 
issue [7]. There are currently two strategies for this treatment: repair or valve replacement [7].
Valve replacements generally exist in two forms: mechanical heart valves (MHVs) or biopros-
thetic (biological) heart valves (BHVs) [9]. There are five categories of biological heart valves: 
autograft, autologous, homografts, pericardial valves, and porcine xenografts [7]. Autograft 
heart valves are implanted using the Ross procedure, which replaces the problematic aortic valve 
with a healthy valve that is already within the patient [10]. To create an autologous heart valve, 
cells from a patient must be harvested and transplanted onto a scaffold using tissue engineering 
techniques. The resulting tissue that has formed within the scaffold is then placed back inside 
the same patient [11]. Homografts that used for valve replacements are typically taken from 
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organ donors. Grafts obtained from these donors, or sources other than the receiving individual 
are known as allografts. Pericardial valves are fabricated from bovine pericardium and are fixed 
onto a stented frame during implantation [12]. Xenografts are any valves transplanted from an 
animal source, including porcine and bovine pericardial valves [12].
Bioprosthetic valves can also be in one of three forms: stented, stentless, and percutaneous 
[13]. Mechanical valves are typically created from non-biological materials like polymers, 
metal, carbon, and various alternatives [9]. Of the two valve replacement types, roughly 
half of U.S. patients receive bioprosthetic valves. These are usually either porcine xenograft 
or bovine pericardial valves. Another 43% of patients undergoing heart valve surgery will 
receive mechanical prosthesis (Table 1) [7].
2.1. Bioprosthetic vs. polymer valves
When choosing between a bioprosthetic and a mechanical valve, there are some important 
factors that should be taken into consideration. These include the patient’s age, preference, 
life expectancy, comorbidities, and indication/contraindication for warfarin therapy [13]. 
MHVs and BHVs not only have different compositions, but also differ in features like throm-
bogenicity, durability, and hemodynamic properties [15]. MHVs have superb durability but 
require lifelong anticoagulation therapy because of their increased risk of thromboembolism, 
thrombotic obstruction, and hemorrhage. In contrast, bioprosthetic valves do not require 
anticoagulation therapy because they are less thromboembolic; however, due to calcific 
Bioprosthetic  
heart valves
Material Purpose Implantation 
methods
In vivo response
Stented Porcine valve 
leaflets and bovine 
pericardium 
fabricated into 
pericardial valves  
are both mounted 
onto a polymer or 
metallic supporting 
stent
Unlike mechanical 
valves, stented valves 
are not susceptible to 
thrombo-embolic effects
Requires open heart 
surgery
These biological valves 
do not present the 
patient with thrombo-
embolic problems 
but they do lead to 
calcification and tissue 
hardening due to 
immune response
Stentless Made from bovine 
pericardium or 
porcine aortic  
valves
Used to improve 
hemodynamics and 
durability of the  
valves
Requires open heart 
surgery
These present the same 
problems in vivo as 
stented valves but have 
been shown to have 
a 10% larger effective 
valve area compared to 
stented valves
Percutaneous Biologic porcine or 
bovine pericardium 
is affixed to a 
supporting stent or 
cage
A less invasive surgery 
for valve replacement 
in patients with high 
operative risks
Implanted into 
the body by a 
percutaneous 
transfemoral 
method
Presents same 
problems as stented 
and stentless but is a 
very novel technique 
and needs further 
investigating
Table 1. Table summarizing the differences between stented, stentless and percutaneous bioprosthetic heart valves [12–14].
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tissue degradation, their durability is finite [13]. MHVs and BHVs last around 20–30 years 
and 10–15 years, respectively. Biological valves are used more often than mechanical valves 
because of their ease of implantation, safety, functionality, and the fact that they do not 
require anticoagulant therapy [7, 15].
Most BHVs used are fabricated from porcine heart valves or from bovine pericardium. While 
bioprosthetic valves are competent, they are still lacking in that they have significant struc-
tural deterioration due to calcification [16]. Younger age, renal insufficiency, mitral valve 
position, and hyperparathyroidism are all predictive factors thought to be associated with 
structural valve deterioration (SVD). Patient age is a major factor of SVD in bioprostheses. 
Implant failure ten years after application occurs in less than 10% of elderly patients, while 
reaching 20–30% in patients less that forty years old [13].
Other factors contributing to calcification are the pre-implantation techniques used on biopros-
thetic valves. For example, prior to implantation, most bovine or porcine valves are decellular-
ized which make them less antigenic; however, this process removes all the endothelial cells 
present. Therefore, adjoining tissue and/or circulating cells cannot then be reseeded after decel-
lularization occurs [7, 17]. Along with decellularization, stabilization of the extracellular matrix 
(ECM) components, and masking of xenogeneic epitopes are important. For this reason, all 
animal pericardium must be treated with specific crosslinking agents such as glutaraldehyde 
prior to implantation. However, glutaraldehyde stimulates many destructive effects such as 
structural damage, cytotoxicity, and calcific deterioration [18]. Because of problems associated 
with prosthetic valves, approximately 60% of all patients receiving heart valve replacements 
will need to have a revision surgery [7]. Also, all studies thus far have neither confirmed nor 
rejected the use of pericardial valves over porcine valves or vice versa (Figure 1) [13].
Figure 1. Image of a porcine bioprosthetic heart valve. (C) is showing calcification, (T) is showing cusp tears, and (S) is 
showing stenosis of the valve [16].
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2.1.1. Mechanism
2.1.1.1. Modes and mechanisms of valve failure
The specific mechanisms leading to VHD are not fully known, meaning it is unclear how 
important genetics, cellular characteristics, and microenvironmental characteristics are in this 
disease. However, in light of recent evidence, it is believed that alterations in developmental 
morphogenesis signaling pathways could play a role in VHD [8]. One affected pathway is 
that of Notch1. The Notch1 pathway is engaged in numerous cell-to-cell communication pro-
cesses. With this pathway being an intercellular signaling mechanism, it is believed that the 
loss of Notch1 results in deformation of leaflet morphology throughout embryo development 
and the inability to suppress calcification during adulthood [19].
One known major cause of failure in bioprosthetic heart valves is calcification [17]. The exact 
mechanism of tissue degeneration leading to calcification is not fully known. However, IgM/
IgG antibodies entering the valve matrix initiate the process. This then leads to deposition of 
macrophages on the valve surface which is followed by collagen breakdown and calcification 
[15]. These macrophages are critical factors in the innate immune response. Macrophages are 
in charge of inducing phagocytosis and killing bacteria. When these macrophages become 
overwhelmed, they induce an inflammatory response [20]. This inflammatory response 
causes an increase in inflammatory cytokines that cause calcification [13]. For this reason, the 
immune system is thought to be a key factor in the initiation of calcification (Figure 2) [15].
Figure 2. This is a theoretical model showing the degenerative, atherosclerotic, and immune rejection processes involved 
in the structural degradation of bioprosthetic heart valves [13].
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To further determine the reason for calcification involved with BHVs, their composition must 
be examined. BHVs are fixed in glutaraldehyde to reduce immunogenicity and ameliorate 
the mechanical strength of the heart valve; however, this fixation reduces antigen presenta-
tion and chemical stabilization by concealing antigens and eventually leading to an influx in 
calcium [9]. Consequently, glycoproteins and other substances are lost during glutaraldehyde 
fixation which allows for the formation of a calcium phosphate precipitate that would not 
occur under normal cardiac conditions [17]. This glutaraldehyde fixation is also thought to 
cause chemical interactions between aldehyde groups, phospholipids and circulating calcium 
ions which can also cause calcification in bioprosthetic valves [15].
Surface heparin has been used as a preventative method for dealing with tissue calcification in 
heart valve replacements. This heparin treatment is meant to replace glutaraldehyde fixation. 
In one study, it was discovered that porcine aortic valves that were pretreated with surface 
heparin showed a decrease in the accumulation of calcium in valve tissue [17]. While the exact 
mechanisms of heparin are unclear, it is thought that the heparin molecules block calcium 
phospholipid-binding sites that glutaraldehyde fixation targets. Ingrowth and antiprolifera-
tive effects are also characteristics of heparin which may potentially influence small muscle 
cell growth during implantation which would indirectly inhibit calcification [17].
In addition to glutaraldehyde fixation causing calcium influx and tissue degradation dete-
rioration, recent studies have suggested that SVD is also due to active mechanisms such as 
atherosclerosis and immune rejection. This immune rejection could be due to bioprosthetic 
valves not being “immunologically inert” [13]. This results in humoral and cellular immune 
responses that lead to tissue disruption and/or mineralization. This would explain why 
younger patients with a more vigorous immune system might experience faster SVD.
Bioprosthetic SVD might also be due to atherosclerotic processes from associated risk factors 
[13]. The oxidation and infiltration of low-density lipoproteins within bioprosthetic tissue might 
trigger an inflammatory process. This would result in osteoblastic differentiation of stem/pro-
genitor cells caused by the oxidized low-density lipoproteins and inflammatory cytokines [13]. 
Another reason for bioprosthetic valve failure is calcific deposits found in tears in the commis-
sural and basal areas of the cusp. Within 15 years of implantation, over 50% of porcine valves 
show some form of functional degradation, usually due to regurgitation caused by these cusp 
tears [15].
2.1.2. Prevention
2.1.2.1. Biomaterial alterations and coatings
One of the major reasons that implants calcify is due to the biocompatibility of the material. 
In several studies, either altering the chemical makeup and properties of the biomaterial or 
coating the material with anticalcification agents have been used to reduce these effects.
Crosslinking surface material of various implants has become a topic of interest in current 
research, specifically because of the mechanical properties it supplies to implants. Crosslinking 
chemistry provides protection to various extracellular matrix components in bioprosthetic 
heart valves in order to retain structural strength [21]. Several crosslinking methods, specifi-
cally crosslinking with glutaraldehyde, provide strength by preventing degradation, but the 
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elastin in the ECM is not protected. This leads to stiffness, tears, and deformations in the 
surface of the material, a condition known as “permanent set” [5]. A modified form of cross-
linking involving treating the surface of biomaterial implants with pentagalloyl glucose does 
not cause damage to collagen or surface deformations. In a study using bovine pericardium 
tissue, the combined cross-linking was prepared by first soaking the tissue in neomycin trisul-
fate and a buffer, then incubating it in a cross-linking carbodiimide solution with pentagalloyl 
glucose. The treated leaflets of tissue were then tested in vivo in rats to determine calcification 
after a thirty day period. Little to no calcification was found on any of the leaflets. The study 
showed the potential benefits of using this cross-linking method to prevent or delay calcifica-
tion in implants, though further data should be collected (Figure 3) [5].
Figure 3. Treating the biomaterial with POSS to form POSS-PCU changes existing receptors so that free calcium ions are 
no longer able to bind, preventing deposition and mineralization [5].
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Another method of preventing calcification is by targeting the free aldehydes present in bio-
prosthetic tissue. As previously mentioned, glutaraldehyde is used to set tissue to be used 
for implants because of the strength it provides, and the aldehydes remaining on the tissue 
are thought to promote calcification [22]. When bovine pericardium is treated with alter-
natives to cap the free aldehydes, the tissue shows significantly reduced levels of calcium 
content and mineralization [23]. Reducing agents such as glycine, glutamate, and sodium 
bisulfite can form a Schiff base and effectively neutralize the aldehydes present [23]. This 
process allows the tissue to maintain its mechanical strength but inhibits the formation of 
calcification [23].
Nanocomposites are growing in popularity for use in biomaterials due to their biocompatibil-
ity and anticalcification properties [24]. Using polyhedral oligomeric silsesquioxane (POSS) 
nanoparticles with poly(carbonate-urea)urethane (PCU) has proven to increase mechanical 
strength, and potentially work as a calcification-resistant material. Figure 3 illustrates the 
treatment of POSS-PCU [24]. These composites have been shown to significantly decrease 
deposition compared to glutaraldehyde-fixed bovine pericardium tissue. The treated tissue 
shows decreased platelet adhesion to its surface compared to typical bovine pericardium, a 
mechanism thought to be associated with calcification resistance [25]. These nanocomposites 
show increased promise for use in biomaterials.
2.2. Tissue engineered and ion-loaded scaffolds
Because of their biocompatibility and regenerative capabilities, tissue engineered scaffolds 
are becoming a popular source for heart valves replacements. There are three different types 
of scaffolds: porous, fibrous, and hydrogels. These can be either acellular or seeded with 
autologous cells to promote regeneration and avoid a negative immune response [7]. A key 
component in the scaffold is its ability to degrade in a controlled time period [7]. The tissue 
can then be regenerated while the synthetic scaffold degrades or is remodeled, leaving behind 
growth and proliferation resembling natural tissue [26].
Tissue-engineered scaffolds seeded with vascular interstitial cells (VICs) have been shown to 
regenerate valvular tissue, while still retaining the alpha-smooth muscle actin (α-SMA) marker 
expressed in smooth muscle cells [7]. The tissue engineered scaffolds have a lower risk of ECM 
damage than the decellularized tissue used in many heart valve implants; therefore, the col-
lagen and fibers behave in a more normal manner, retaining their smooth muscle phenotype. 
Porosity can be controlled, compared to the unintentional porosity created in decellularized 
tissue, making the scaffolds more resistant to calcification [7].
These scaffolds can be manipulated before entering the body, from seeding them with autolo-
gous cells to promote new growth to loading them with ions as a form of drug delivery to 
mitigate negative responses post-implantation. Metal ions, including iron, aluminum, and 
magnesium, are gaining popularity in current research because of their ability to bind to 
forming hydroxyapatite crystals in the serum and prevent further deposition [27]. Though 
the mechanism is not fully understood, it is hypothesized that ions such as magnesium bind 
where calcium typically would, preventing calcium deposits [28]. They also are thought to 
interrupt alkaline phosphatase activity [27]. These ions often exist naturally in the body for 
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this process, but by loading tissue-engineered scaffolds with different metals (aluminum, 
magnesium, iron) they can specifically target calcium deposition at the site of the implant to 
prevent failure. The problem that rises with this design is that, after implantation, there is no 
way to reload the matrices with more ions, so it cannot act as a long term inhibitor.
3. Urinary
3.1. Urinary tract materials
In the entire urinary system, the organs most commonly and significantly affected by calci-
fications are the kidneys, followed by ureters, and then the urinary bladder. Urinary tract 
calculi are formed when the urine is supersaturated with salt and minerals such as calcium 
oxalate, struvite (ammonium magnesium phosphate), uric acid, and cysteine [29]. This super-
saturation can be caused by a variety of genetic and dietary factors, urinary calcium excretion, 
and environmental triggers [30]. Urinary calculi are solid particles in the urinary system that 
cause pain, nausea, vomiting, hematuria, and chills/fever due to secondary infection.
Urinary tract calcification is organized in three different categories: renal calcification, ureteral 
calcification, and bladder calcification. These are further classified by their orientation, position, 
shape, size, mobility, opacity, chemical composition, and location in the kidneys, ureters, or 
bladder, and their relation to pathologic conditions [31]. Calcification in the urinary tract can 
also occur from infection of the implants. Healthcare associated infections are the fourth leading 
cause of disease [33]. Studies indicate that biofilm infections cause up to 80% death [33]. One of 
the leading causes of infection is the insertion of catheters and ureteral stents [33].
3.1.1. Mechanism
3.1.1.1. Urinary infection mechanisms
Catheters and stents used in patients are subject to biofilm formation when different particles 
in the urine, blood, or surrounding tissue attach to the surface of the implant. Biofilms begin 
to form when colonized bacteria attaches to the surface of the device, altering the surface 
properties [32]. Once attached, the bacteria binds with target molecules and, after an extended 
period of time, the attachment becomes permanent and the process is irreversible. Overtime, 
as the biofilm becomes more developed, it will repeat these processes to form a new biofilm 
formation on an unpopulated area of the implantation device [34].
One of the main reasons for encrustation of a device is infection due to bacteria that produce 
urease. This enzyme uses urea to create an alkaline environment from ammonia, raising the pH 
[35]. E. faecalis, Proteus mirabilis, Staphylococcus aureus, and Candida tropicalis are considered the 
strongest strains to form biofilms; however, P. mirabilis is hydrolyzes urea ten times faster than 
the rates of other strains [34]. Under these conditions, hydroxyapatite and struvite crystals form 
on the surface of the device, resulting in encrustation [34]. This process will continue and repeat 
until the flow of urine is blocked due to encrustation resulting in the complete device failure [35].
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Encrustation of ureteral stents occurs for a variety of reasons. One reason is the failure of 
patients to return for stent removal after surgery or inadequate counsel by professional 
healthcare [36]. The material of the stent may also contribute to encrustation. Silicone con-
taining stents seems to be more resistant to encrustation, followed by polyurethane, silitek, 
percuflex, and hydrogel coated polyurethane [36]. Stents fracturing after being in situ for 
a long period due to hardening and loss of tensile strength can also be another reason for 
encrustation. Other factors that contribute may include urinary composition (hypercalciuria, 
hyperoxaluria, hypocitraturia, homocystinuria, and hyperuricosuria), history of urolithiasis, 
and congenital urinary tract anomalies [37].
3.1.2. Prevention
3.1.2.1. Urinary implant coatings
Coatings of the urinary implantation devices are one of approaches that prevents bacterial 
adherence. Surface coatings of the devices inhibit bacterial biofilm formation to prevent infec-
tion and encrustation [38]. The coating needs to have certain properties to inhibit bacterial 
adherence which includes biocompatible, resists biofilm formation, and antimicrobial [39].
Hydrogels are hydrophilic, cross-linked polymers capable of absorbing large amounts of liquid. 
They form a thin layer of water on the surface of the device, preventing biofilm formation and 
bacterial adherence [34]. Studies have shown hydrogel-coated catheters have less bacterial adher-
ence compared to non-hydrogel coated catheters [40]. In addition, hydrogel-coated catheters also 
cause less irritation and inflammation [34].
Similar to hydrogels, antimicrobial peptides (AMPs) are hydrophilic polymers that have anti-
biotic resistance which inhibits bacterial adhesion [39]. In one study, AMPs were coated on 
titanium implants and inhibited bacterial adhesions both in vitro, and in vivo using rat models. 
In addition to inhibiting bacterial growth, it also has wound healing benefits. However, there 
are some conditions with AMPs that include potential local toxicity, pH sensitivity, suscepti-
bility to proteolysis, and high cost of synthesis [34].
Polyvinylpyrrolidone (PVP) is also hydrophilic and has excellent lubricant properties. Therefore, 
the implantation device has less bacterial adhesion and encrustation in vivo compared to 
uncoated catheters [34]. Heparin is a glycosaminoglycan which is a natural inhibitor of crys-
tallization. Naturally, heparin is considered to prevent bacterial attachment and encrustation; 
however, studies concluded that there is not a significant decrease in bacterial adherence despite 
its overall good quality [38].
On the contrary, hyaluronic acid shows promising results in vitro. Hyaluronic acid is a type 
of glycosaminoglycan that inhibits nucleation, growth, and aggregation of salts. Covalently 
bound hyaluronic acid catheters increase hydration, while decreasing adsorption of proteins 
and bacterial adhesion. Even though hyaluronic acid coating shows promising results, it has 
yet to be fully analyzed. Gendine is another antimicrobial coating that contains gentian violet 
and chlorhexidine [34]. Compared to uncoated controls, devices that are coated in gendine are 
resistant to the adherence of multi-drug-resistant bacteria [34].
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Researchers are continuously searching for an ultimate biocompatible material that can 
substitute segments of the urinary tract [41]. This involves urinary system cells or other cell 
sources that can be seeded onto biodegradable scaffolds [42]. Experts have reported that cells 
isolated from urine can express smooth muscle, endothelial and interstitial cells, and mark-
ers of urothelial [42].The ideal biomaterial has to be biocompatible and biodegradable, pro-
mote vascular regeneration, nerve regeneration, and cellular differentiation; also, it should 
be watertight and stretchable, resist encrustation and biofilm formation, and regain its shape 
[41]. However, most biomaterial includes natural collagens, and natural collagens scaffolds 
cannot maintain their physical properties in an in vivo environment resulting in graft failure 
or formation of fibrosis [43]. There is no ideal biomaterial available yet, but they can be modi-
fied to enhance biological properties for cellular integration. Smart polymers are also optimal 
for use in urinary construction [41].
4. Diseased state
In addition to affecting different biomaterials and biosynthetic implants, calcification also 
occurs naturally throughout the cardiovascular and the urinary system due to various states 
and diseases.
Cardiovascular disease is the leading cause of death in the United States, with a high mortality 
rate among end stage renal disease (ESRD) patients [44]. ESRD and other forms of kidney disease 
are marked by elevated levels of calcium phosphate in the serum, leading to mineral deposition 
and calcification of the arterial wall. This occurs as vascular smooth muscle cells differentiate from 
their typical phenotype to osteoblast-like cells that cause bone formation in atypical regions [45]. 
This risk increases with patients on dialysis, due to the fact that important calcification-inhibitory 
molecules, such as Fetuin-A, are stripped from the body [45]. This high level of phosphate also 
leads to the activation of the Wnt signaling pathway. When high levels of phosphate accumulate 
in smooth muscle cells, 𝛽-catenin is upregulated [46]. This leads to an increased expression of 
bone-morphogenetic protein 2 (BMP-2) and runt-related transcription factor-2 (Runx2) in smooth 
muscle cells, though the two factors are typically only seen in bone cells [47].
Primary hyperparathyroidism (PHPT), often associated with cardiovascular disease, is another 
condition potentially linked to calcification. It has been observed that as levels of parathyroid 
hormone increase in PHPT patients, there is an associated increase in abdominal aortic calci-
fication [48].
Another form of calcification associated with imbalance of minerals in the body is nephrocal-
cinosis. When calcium intake increases and it begins to build up in the kidneys, it leads to the 
deposition of minerals in the renal parenchyma and tubules [49]. These calcified regions are 
also formed through an osteopontin deficiency. This calcification in the urinary system can 
contribute to renal dysfunction and potentially lead to ESRD [49].
Calcification of both the vascular and urinary system in the body can be driven by various 
diseases and conditions, typically due to some sort of mineral or chemical imbalance in the 
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serum. Taking this into account, as well as the increased rate of calcification seen in bio-
implants, it is critical for current research to move toward both prevention and treatment 
of this phenomenon.
4.1. Mechanism
4.1.1. General mechanisms
Calcification is a pathological process that occurs with an imbalance of several genetic, 
chemical, and physical properties. The process can depend on the levels of proteins and 
ions present in the serum, like metal ions that bind with hydroxyapatite or proteins that 
chaperone free calcium and phosphate particles. It can also be induced by physical damage 
to cells and tissue, whether by chemical means or foreign implants in the body. Though 
many individual factors are associated with the formation of mineral deposits and calci-
fication in the body, the mechanisms inducing calcification are still being researched and 
understood.
Vascular calcification (VC) is a prominent issue affecting both the intimal and medial layers of 
the arterial wall. Intimal calcification is usually associated with plaque rupture and thicken-
ing of the endothelium layer in the vessels while medial calcification occurs as smooth muscle 
cells differentiate into osteoblast-like cells, which are associated with bone growth. This phe-
notypic switch in the medial layer is often associated with various osteogenic predecessors 
[50].
Osteoprotegerin (OPG) is a glycoprotein that works by inhibiting bone resorption, and an 
increase in OPG is often associated with an increase in calcification [51]. It participates in the 
OPG/RANK/RANKL pathway to act as a decoy receptor binding to RANKL, where RANK is 
supposed to bind. This in turn prevents RANK’s intended mechanism of osteoblast differen-
tiation into osteoclasts [51].
BMP-2 is also thought to play an important role in VC, since it is expressed in higher levels in 
chronic kidney disease patients, and is a part of the Wnt/β-catenin pathway [52]. Typically, it 
is associated with bone and tooth formation, but the high phosphate levels in uremic patients 
activate this pathway and causes BMP-2 expression.
Apart from the osteogenic markers and factors associated with calcification is another major 
protein, matrix Gla protein (MGP). In its activated form, it antagonizes BMP-2 signaling as 
a negative feedback regulator due to its carboxylated glutamate residues [53]. It also acts by 
binding to forming hydroxyapatite crystals to prevent deposition and calcification. However, 
it must be carboxylated by vitamin-K in order to be active, which may be why vitamin-K defi-
cient kidney disease patients show calcified vessels [54].
In biomaterials, the surface structure of the material can determine the post-implantation 
calcification. Materials with a higher porosity have the increased potential for calcification, 
because the larger pores allow for more calcium deposition [55].
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4.2. Prevention
4.2.1. Dietary changes
Because most causes of calcification are rooted in a mineral imbalance, dietary modifications or 
supplementation are currently being studied for potential use in attenuating the effects of calci-
fication in different regions in the body. Magnesium ions are known to inhibit calcium deposi-
tion, though the mechanism is not clearly understood [56]. When supplied to vascular smooth 
muscle cells, the rate of cell damage by apoptosis is significantly decreased as the magnesium 
levels increase in the media [57]. Decreasing the rate of apoptosis decreases arterial stiffness and 
calcification since apoptosis of smooth muscle cells often leads to the disruption and remodel-
ing of plaque in the arteries [58]. Increased magnesium levels also decrease the expression of 
Runx2, inhibiting the differentiation of smooth muscle cells into osteoblast-like cells [57].
In a Framington Heart Study of 2695 participants, a dietary assessment was used to measure 
magnesium intake levels and determine whether adding the supplement could prevent or 
inhibit calcification. It was found that both coronary artery and abdominal aortic calcification 
decreased as magnesium intake increased, with a 22% decrease in coronary artery calcifica-
tion for every 50 mg increase in daily magnesium intake, and significant decrease in abdomi-
nal aortic calcification with magnesium increase [59]. Even though the mechanism is not fully 
understood, the metal does correlate with an inhibition of calcification.
MGP is another inhibitor of calcification that prevents the differentiation of vascular smooth 
muscle cells into osteoblasts [60]. However, MGP can only inhibit calcification if it is activated via 
carboxylation, making it a vitamin K-dependent protein. In patients with chronic kidney disease, 
there is a vitamin K deficiency and MGP remains inactivated [54]. For this reason, vitamin K was 
investigated as a dietary supplement to activate circulating MGP and inhibit calcification.
In a randomized, controlled trial, male and female patients were given either a control or vita-
min K supplement, and CT scans were used for analysis of calcification levels [61]. Blood sam-
ples were also taken and analyzed with a radioimmunoassay to determine MGP levels in the 
serum. While results showed that the supplement reduced the levels of calcification currently 
existing, it did not prevent the new formation of calcium deposits. MGP levels also showed no 
significant difference between the control and vitamin K group [61]. This shows that vitamin K 
could be used as a supplement to slow the progression of existing calcium deposits, though it 
has not been proven to prevent the formation of new calcification.
4.2.2. Protein therapy
Several naturally occurring proteins in the body act as inhibitors of calcification. MGP, as 
previously mentioned, is a naturally occurring inhibitor of calcification, requiring carbox-
ylation to prevent osteoblastic-differentiation. Fetuin-A, also known as alpha-2-Heremans-
Schmid glycoprotein, is another protein that acts by binding to free calcium and phosphate 
particles in the serum and preventing deposition [62]. In dialysis patients, fetuin levels in the 
body are significantly lower than in healthy patients, correlating with an increase in vascular 
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calcification [63]. Because of this correlation, fetuin has been considered as a potential thera-
peutic protein, as treatment for vascular calcification [4].
Osteopontin (OPN) is a protein associated with bone remodeling and resorption. When 
phosphorylated, it can easily bind with calcium ions to prevent calcification [49]. It resists 
calcification in a dose-dependent manner when supplemented to smooth muscle cells to 
protect their phenotype, and is currently being researched to determine its therapeutic abili-
ties [49].
4.2.3. Drug-coated stents and balloon angioplasty
There are two main classifications of stents: bare metal stents and drug-eluting stents. The 
latter has been used to treat calcification and prevent restenosis by incorporating anti-prolif-
eration and anti-inflammatory agents into the material of the stent [64]. However, in regions 
of high calcification, it is common for the stent to improperly deploy within the vessel, leading 
to further plaque build-up and implant failure [64].
In order to prevent improper placement of the stent and reduce adverse effects, drug-coated 
angioplasty balloons are often favorable to stents. Balloon angioplasty is a common treat-
ment for calcification in the arteries, working as an immediate clearing of vessels to allow 
blood flow [65]. By modifying this design and using drug-coated balloons, obstructions in 
the vessels can be immediately broken up while also delivering various agents to prevent 
the return blockage without leaving a permanent implant behind [66]. Paclitaxel-coated 
balloons have been used because of the drug’s ability to stop cell division so that when it is 
delivered to regions with increased plaque buildup, further growth is inhibited. The drug 
is delivered uniformly to the arterial wall with immediate release and incorporation into 
the tissue [67].
5. Assessment
5.1. Assessment of biomaterials calcification
Many different techniques are used to investigate and examine the calcification of biomateri-
als. This can be done with either morphologic or chemical techniques. Morphological testing 
yields important qualitative information like the detection, characterization, and distribu-
tion sites of calcific deposits as detailed below, but still lacks quantitative information. While 
chemical techniques reveal more qualitative data such as identification of elemental composi-
tion and determination of crystalline mineral phases, they require a complete ruination of the 
tissue specimen [68]. Furthermore, techniques such as microcomputer tomography (micro 
CT) are recent technologies available for both in vitro and in vivo samples that are non-invasive 
and non-destructive [68].
Morphological assessment of calcification uses many different techniques, including scanning 
electron microscopy (SEM), radiographs (X-rays), light microscopy, transmission  electron 
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microscopy (TEM), and microcomputer tomography (micro CT) [68, 69]. Calcific deposit dis-
persal can be seen from X-rays, and most calcification is studied using morphological tech-
niques done outside of the body once the implantation is removed. As mentioned previously, 
calcific deposit morphology, quantification, and localization can be seen from micro CT. Both 
X-ray and CT techniques require gross specimen sample preparation. Light microscopy is 
used in conjunction with various staining techniques to identify mineral deposits with either 
a calcium or phosphorus-specific stains. Alizarin red is a calcium-specific stain and von Kossa 
is a phosphate-specific stain [68]. Hematoxylin/eosin, Mallory’s trichrome and alcian blue 
stains are known as histological stains associated with light microscopy, both readily avail-
able and easily applied to tissue [69].
Two types of microscope techniques mentioned previously, SEM and TEM, are electron 
microscopes that use a highly focused electron beam contained in a vacuum to passes the 
specimen [68]. In one study, SEM was used to analyze bovine pericardium samples in vitro 
for calcification using SEM. To prepare the samples for analysis, they were first soaked in a 
simulated body fluid containing ionic concentrations similar to natural body plasma fluid, 
then placed in a controlled environment. After seven days, samples were rinsed, deionized, 
and frozen in liquid nitrogen. Finally, samples had to be lyophilized before SEM analysis 
could be performed [70]. Other methods of calcification testing include Fourier transform 
infrared spectroscopy, which is used to determine structure coatings and x-ray diffraction of 
lyophilized samples using a diffractometer with Cu-Kα radiation [70].
6. Future works
There are many important factors to review when looking at heart valve replacements. Cost 
should be considered since valvular heart disease is prominent worldwide, especially in 
underdeveloped countries. Post-implantation failure is another factor, largely due to age of 
the patient given that children and young adults have a more competent immune system 
and experience a higher rate of BHV failure. In some countries lacking adequate ways of 
monitoring patients, mortality is an increased risk [9]. Calcification is also a major cause 
of deterioration in BHV replacements. The complications associated with calcification of 
artificial heart valves can lead to the need for revision surgery in patients. Mechanical valve 
replacements potentially require additional surgery due to thrombosis, thromboembolism, 
or spontaneous bleeding can occur; additionally, these replacements require lifelong anti-
coagulation therapies [9].
For these reasons, experts are trying to further understand the mechanism of biomaterial 
calcification and exploring more biocompatible materials. As mentioned before, there is not 
a specific mechanism that leads to VHD, so further understanding of the various processes 
involved will improve treatment strategies that include tissue engineering and drug-coated 
biomaterials [8]. Some studies have reported that tissue engineering scaffolds have similar 
uniaxial mechanical properties but need more investigation with biaxial mechanical proper-
ties that are more related to soft tissue. There are also clinical studies that combined both 
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synthetic and natural polymers to construct a scaffold that could be similar to the native 
mechanical properties of a heart valve which may improve their biocompatibility [7]. Another 
approach to prevent calcification is to modify the surface of the device; for example, heparin 
can be used to inhibit tissue calcification [69].
In addition, urinary stents and catheters need more attention to overcome the two main causes 
that lead to calcification: infection and encrustation. Currently, studies are focusing on inno-
vating stent designs, biomaterials, and surface coatings [41]. Many studies have attempted 
to combine multiple antimicrobial agents into one coating, for example using several anti-
biotics. Another approach that most researchers have recently used is constructing urinary 
tissue from organ-specific stromal cells resulting in better biomechanical properties similar 
to human than non-specific stromal cells [71]. However, most biomaterials include natural 
collagens that are unable to maintain the same physical properties, resulting in graft failure 
[43]. Further investigation and clinical studies are needed to introduce the ideal biomaterials 
and coating [34].
In conclusion, further development will include better understanding of VHD to improve 
our treatment strategies. More trials and clinical studies are needed to create an “ideal” bio-
material for tissue engineering and drug-coated biomaterials. Additional experiments will be 
needed to test innovating stent designs, heart valves, and surface coatings to treat implanta-
tion calcification.
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